Cellular senescence in cancer treatment: friend or foe?
- 15 January 2004
- journal article
- review article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 113 (2), 169-174
- https://doi.org/10.1172/jci20784
Abstract
Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.Keywords
This publication has 55 references indexed in Scilit:
- Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemiaBlood, 2003
- Association of increased autophagic inclusions labeled for β-galactosidase with fibroblastic agingExperimental Gerontology, 2003
- Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entryNature, 2003
- Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular SenescenceCell, 2003
- Apoptotic Cells Induce Migration of Phagocytes via Caspase-3-Mediated Release of a Lipid Attraction SignalCell, 2003
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- The role of ATM in DNA damage responses and cancerOncogene, 1998
- DNA damage activates p53 through a phosphorylation–acetylation cascadeGenes & Development, 1998
- Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4aCell, 1997
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature, 1993